ArticleInternational journal of molecular sciences2026
Naringenin Enhances the Inhibitory Effect of Regorafenib on HepG2 Hepatocellular Carcinoma Cell Viability with Modulation of E-Cadherin and MRP1 Gene Expression.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a life-threatening malignancy. Although regorafenib is used for HCC treatment, its clinical utility is limited by significant adverse effects. This study evaluated whether combining regorafenib with naringenin could enhance its anticancer activity against HepG2 cells. This study included seven groups of HepG2 cancer cells: an untreated control group, a naringenin-treated group (100 μM), a regorafenib-treated group (1 μM), and four groups receiving naringenin (100 μM) combined with decreasing concentrations of regorafenib (1, 0.75, 0.5, and 0.25 μM). Cell viability and the expression of E-cadherin and MRP1 were assessed. All treatments significantly reduced cell viability compared with the control group, with greater inhibition observed in the combination-treated groups than in the monotherapy groups. Combination treatment also increased E-cadherin expression and decreased MRP1 expression. The combination of regorafenib (1 μM) and naringenin (100 μM) exhibited the greatest growth inhibition, the highest E-cadherin, and the lowest MRP1 expression levels. Notably, combining the IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.